Skip to main content
OpenTrials
Completed

NCT Number: NCT02688140

Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia

Acute promyelocytic leukemia (APL) is a rare subtype of acute myeloid leukemia (AML) characterized by consistent clinical, morphologic, and genetic features. According to the FAB classification APL is designated as"M3 leukemia" and assigned to the WHO defined type of AML with recurrent cytogenetic abnormalities, "acute promyelocytic leukemia with t(15;17)(q22;q12), (PML/RARα) and variants".

Despite the dramatic progress achieved in frontline therapy of APL with ATRA plus anthracycline-based regimens, relapses still occur in approximately 20% of patients. Moreover, these regimens are associated with significant toxicities due to severe myelosuppression frequently associated with life-threatening infections and potentially serious late effects including development of secondary MDS/AML. In a recent randomized clinical trial in low/intermediate-risk APL (WBC ≤ 10 GPt/l APL0406 trial) a combination of arsenic trioxide (ATO) and ATRA has been shown to result into better survival with significantly lower toxicity rates compared to the standard ATRA + idarubicin (AIDA) therapy. Inspired by the results of this trial the investigators intend to perform a randomized study in high-risk APL (WBC at diagnosis > 10 GPt/l) comparing standard AIDA-based treatment with ATO/ATRA combination including low-doses idarubicin during induction. The investigators propose a modified ATO/ATRA protocol with the addition of two doses of IDA (50% compared to standard AIDA induction) for induction because of the anticipated need of adding anthracyclines to control hyperleukocytosis and to achieve long-term disease control in this high-risk APL population. This is followed by 4 cycles of ATO/ATRA consolidation therapy. As in the APL0406 study for low/intermediate-risk patients the investigators expect less severe hematologic toxicity and treatment-related mortality resulting in an improved outcome for patients in the experimental arm. Furthermore, from the start of consolidation, these patients (in contrast to the standard arm) can be treated on an outpatient basis, which is also considered to be associated with an improved quality of life. The study will be conducted as a European intergroup study.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acute Promyelocytic Leukemia Hematologic Diseases Hemic and Lymphatic Diseases Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute Leukemia, Promyelocytic, Acute Neoplasms Neoplasms by Histologic Type

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

French-Belgian-Swiss APL study group, All Participating Sites, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Informed consent
  • Women or men with a newly diagnosed APL by cytomorphology, confirmed by molecular analysis*
  • Age ≥ 18 and ≤ 65 years
  • ECOG performance status 0-3
  • WBC at diagnosis > 10 GPt/l
  • Serum total bilirubin ≤ 3.0 mg/dl (≤ 51 µmol/l)
  • Serum creatinine ≤ 3.0 mg/dl (≤ 260 µmol/l)
  • Women must fulfill at least one of the following criteria in order to be eligible for trial inclusion:
  • Post-menopausal (12 months of natural amenorrhea or 6 months of amenorrhea with Serum FSH > 40 U/ml)
  • Postoperative (i.e. 6 weeks) after bilateral ovariectomy with or without hysterectomy
  • Continuous and correct application of a contraception method with a Pearl Index of <1% (e.g. implants, depots, oral contraceptives, -intrauterine device - IUD)
  • Sexual abstinence
  • Vasectomy of the sexual partner
  • The confirmation of diagnosis at genetic level (microspeckled PML nuclear distribution by PGM3 monoclonal antibody and/or PML/RARa fusion by RT-PCR or fluorescence in situ hybridization (FISH) and/or demonstration of t(15;17) at karyotyping) will be mandatory for patient eligibility. However, in order to avoid delay in treatment initiation, patients can be randomized on the basis of morphologic diagnosis only and before the results of genetic tests are available

Exclusion criteria

  • Patients who are not eligible for chemotherapy as per discretion of the treating physician
  • APL secondary to previous radio- or chemotherapy for non-APL disease
  • Other active malignancy at time of study entry (exception: basal-cell carcinoma)
  • Lack of diagnostic confirmation at genetic level
  • Significant arrhythmias, ECG abnormalities:
  • Congenital long QT syndrome;
  • History or presence of significant ventricular or atrial tachyarrhythmia;
  • Clinically significant resting bradycardia (<50 beats per minute)
  • QTc >500msec on screening ECG for both genders (using the QTcF formula detailed on protocol)
  • Right bundle branch block plus left anterior hemiblock, bifascicular block
  • Other cardiac contraindications for intensive chemotherapy (L-VEF <50%)
  • Uncontrolled, life-threatening infections
  • Severe non controlled pulmonary or cardiac disease
  • Severe hepatic or renal dysfunction
  • HIV and/or active hepatitis C infection
  • Pregnant or breast-feeding patients
  • Allergy to trial medication or excipients in study medication
  • Substance abuse; medical, psychological or social conditions that may interfere with the patients participation in the study or evaluation of the study results
  • Use of other investigational drugs at the time of enrolment or within 30 days before study entry

Treatment and study plan

arsenic trioxide

Drug

Other names: ATO, Trisenox (R), As2O3

Idarubicin

Drug

Other names: IDA

Cytarabine

Drug

Other names: Ara-C

Tretinoin

Drug

Other names: all-trans retinoic acid, ATRA

Mitoxantrone

Drug

Other names: MTZ

mercaptopurine

Drug

Other names: 6-Mercaptopurine, 6-MP

methotrexate

Drug

Other names: MTX

Primary outcomes

  1. Event-free survival

    Time frame: From date of randomization until the date of first documented event, assessed up to 66 months

    events are: no achievement of haematological complete remission after induction therapy; no achievement of molecular remission after the last consolidation course; relapse; death including early death or development of secondary AML or MDS

Secondary outcomes

  1. Rate of hematological complete remission

    Time frame: up to 60 days, from date of randomization until end of induction therapy

  2. Rate of early death within 30 days after randomization

    Time frame: up to 30 days after randomization

  3. Rate of overall survival (OS)

    Time frame: at 2 years

  4. Rate of cumulative incidence of secondary MDS or AML

    Time frame: assessed up to 66 months, from date of randomization until occurance of secondary AML or MDS

  5. Rate of cumulative incidence of relapse (CIR)

    Time frame: at 2 years

  6. Incidence of hematological and non-hematological toxicity

    Time frame: assessed up to 30 months after randomization

  7. Rate of molecular remission after the last consolidation cycle

    Time frame: up to 256 days after randomization

  8. Assessment of acute promyelocytic leukemia/RARa transcript level reduction after induction therapy until end of study

    Time frame: assessed up to 30 months after randomization

  9. Quality of Life at the end of induction therapy until the end of study

    Time frame: assessed up to 30 months after randomization

  10. To investigate differences in the immune reconstitution between the two arms

    Time frame: assessed up to 30 months after randomization

  11. Total hospitalization days during therapy

    Time frame: assessed up to 30 months after randomization

Sponsors and collaborators

Lead sponsor

Technische Universität Dresden

Other

Collaborators

  • German Federal Ministry of Education and Research
  • Groupe Francophone des Myelodysplasies
  • Gruppo Italiano Malattie EMatologiche dell'Adulto
  • HOVON - Dutch Haemato-Oncology Association
  • Programa para el Tratamiento de Hemopatías Malignas
  • Teva Pharmaceuticals Europe

Registry information

Official study title

A Randomized Phase III Study to Compare Arsenic Trioxide (ATO) Combined to ATRA and Idarubicin Versus Standard ATRA and Anthracyclines-based Chemotherapy (AIDA Regimen) for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia

Acronym: TUD-APOLLO-064

Important dates

Study start
2016
Primary completion
2025
Study completion
2025
First posted
Feb 23, 2016
Registry last updated
May 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.